



COPY OF PAPERS
ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date indicated below.

Nancy Malsich
Nancy Malsich

2/1/02
Date

Applicant: Boger

Serial No.: 10/001,611

Filed: October 30, 2001

For: SYNTHESIS OF CC-1065/
DUOCARMYCIN ANALOGS

)
)
) Group: 1626

)
)
) Examiner: Unassigned

)
)
) Our Ref.: TSRI 626.1 D1

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Information Disclosure Statement in compliance therewith.

Pursuant to 37 CFR §1.98(d), enclosed herewith is a copy of 1) the Information Disclosure Statement and 2) the accompanying PTO Form 1449 filed in the application 09/581,049. Application 09/581,049 was filed on July 10, 2000, and has issued as U.S. Patent No. 6,310,209, to which the present application is related by division. Also, pursuant to 37 CFR §1.98(d), copies of the above references are not submitted herewith, as they are available in the related patent application 09/581,049.

Applicants understand that the interpretation given to each

RECEIVED
MAR 06 2002
TECH CENTER 1600/2900

reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application and/or before the mailing date of a first Office Action.

Also, in accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,

Feb 1, 2002
Date

Donald G. Lewis
Donald G. Lewis, Reg. No. 28,636

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937

RECEIVED
MAR 06 2002
FBI
FEDERAL BUREAU OF INVESTIGATION
U.S. DEPARTMENT OF JUSTICE
WASHINGTON, D.C. 20535
TELEPHONE (202) 344-3121
FAX (202) 344-3122
WWW.FBI.GOV

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.